Thermo Fisher Scientific’s microarray solution to boost multi-omics research

Image Credit: Siliconindia

Announcement 

Thermo Fisher Scientific, a recognised expert in delivering science, has launched the Applied Biosystems SwiftArrayStudio microarray analyser. The analyser is engineered for scalable and quick sample analysis. In connection with two new arrays, the Applied Biosystems Axiom PangenomePro array and the Applied Biosystems Axiom Pharmacopro array, this new analyser merges four major genotyping processes into one individual, unified device, allowing researchers to work towards the vast populations for the genome-wide association studies (GWAS). Further, this will leverage the groundbreaking exploratory division in pharmacogenomics that will fuel the next-generation medicine in the near future.

As genetic science has advanced, researchers seek a quick, simple way to examine samples. The traditional pattern delays the completion and accelerates the need for expanded hands-on durability. The huge labs face differences in customer needs, calling out for specialised expertise and various instruments for the best results.

New solutions’ potential

The SwiftArrayStudio microarray analyser allows labs to ease and perform scaling throughput and utilise the performance with the changing demands without compromising data quality. The all-around platform serves in less than 30 hours via a fancy, simple use design that mitigates practical time by 40%. This quality reduces complexity and price, supporting researchers to create high-quality data within less time and effort. The analyser reevaluated the microarray technology’s potential. Its improved flexibility and features allow scientists to uncover new research ideas like population scaling, matters of pharmacogenomics, and genotyping. This will give a new ray of hope to introduce new treatment to the vast population.

Healthcare company Leaders’ statements

The MD, founder and chief executive officer of RPRD diagnostics, Ulrich Broeckel, said, “The SwiftArrayStudio genotyping platform provides spectacular advantages mainly for robust pharmacogenetics genotyping, a key matchable pharmacogenetics gene, along with the CPIC guidelines. Including various ADME genes for research applications with ocean deep thorough coverage of rare and common variants, enabling recognition of mitigated and rare frequent haplotypes. Further, merged with the potential to process a range of medium to high sample throughput, this provides an excellence that is beneficial for pharmacogenetics.”

The president, genetic sciences, Thermo Fisher Scientific, Rosy Lee, said, “For years and years, our creativity in genomics and genetic research has paved the way for new approaches from the scientists' perspective on how they discover biology and serve new potential to applied markets. This new next-generation microarray platform has given us a chance to reevaluate what’s possible.”